Keith W. Pratz

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat et al. · New England Journal of Medicine · 2020 · 2.8K citations · Full text

Medicine, Pharmacotherapy, Medical Oncology +3

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Courtney D. DiNardo, Keith W. Pratz, Vinod Pullarkat et al. · Blood · 2018 · 1.9K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

Courtney D. DiNardo, Keith W. Pratz, Anthony Letai et al. · The Lancet Oncology · 2018 · 712 citations

Medicine, Hematology, Pharmacology +9

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Margaret O’Donnell, Martin S. Tallman, Camille N. Abboud et al. · Journal of the National Comprehensive Cancer Network · 2017 · 655 citations · Full text

Medicine, Hematology, Oncology +16

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Merryl Cramer et al. · Blood · 2009 · 644 citations · Full text

Medicine, Medicinal Chemistry, Oncology +14